脂蛋白(a)与PCSK9抑制剂在LDL-C名义达标患者中的获益
本文为ODYSSEY Outcomes试验的事后分析,评估在优化他汀治疗下LDL-C接近70 mg/dL的近期急性冠脉综合征患者中,加用阿利西尤单抗的获益是否受脂蛋白(a)水平影响。结果显示,仅当脂蛋白(a)至少轻度升高(>13.7 mg/dL)时,PCSK9抑制才带来额外的临床获益。
要点
- LDL-C接近70 mg/dL者,脂蛋白(a)>13.7 mg/dL时阿利西尤单抗显著降低MACE。
- 脂蛋白(a)≤13.7 mg/dL者未见显著获益,治疗与脂蛋白(a)存在交互作用。
- LDL-C≥70 mg/dL亚组中,不同脂蛋白(a)水平的获益差异不显著。
核心结论
- 在近期急性冠脉综合征且优化他汀治疗下LDL-C接近70 mg/dL的患者中,PCSK9抑制仅在脂蛋白(a)浓度至少轻度升高时提供增量临床获益。
研究设计与样本
- ODYSSEY Outcomes为阿利西尤单抗对比安慰剂的随机试验,纳入18,924例近期急性冠脉综合征且接受优化他汀治疗的患者。
- 本分析为事后分析:4,351例(23.0%)筛选或随机化时LDL-C<70 mg/dL(中位69.4 mg/dL,四分位距64.3-74.0 mg/dL);14,573例(77.0%)两次测定均≥70 mg/dL(中位94.0 mg/dL,四分位距83.2-111.0 mg/dL)。
主要发现
- 低LDL-C亚组中,基线脂蛋白(a)高于中位(13.7 mg/dL)的安慰剂组MACE率为4.2/100患者年,低于或等于中位者为3.1/100患者年。
- 低LDL-C亚组相应校正治疗风险比为0.68(95%CI:0.52-0.90)与1.11(95%CI:0.83-1.49),治疗与脂蛋白(a)对MACE的交互作用P=0.017。
- 高LDL-C亚组中,脂蛋白(a)>13.7 mg/dL与≤13.7 mg/dL的安慰剂组MACE率分别为4.7和3.8/100患者年,校正治疗风险比为0.82(95%CI:0.72-0.92)与0.89(95%CI:0.75-1.06),交互作用P=0.43。
临床怎么用
- 对优化他汀治疗后LDL-C接近70 mg/dL的近期急性冠脉综合征患者,可检测脂蛋白(a)以识别可能从PCSK9抑制剂获益者。
- 脂蛋白(a)≤13.7 mg/dL且LDL-C接近70 mg/dL者,加用PCSK9抑制剂的增量获益不显著。
局限性
- 本分析为事后分析,脂蛋白(a)分组基于中位数,结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. OBJECTIVES: In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of adding the proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients with LDL-C levels near 70 mg/dL. Effects were evaluated according to concurrent lipoprotein(a) levels. METHODS: ODYSSEY Outcomes compared alirocumab with placebo in 18,924 patients with recent acute coronary syndromes receiving optimized statin treatment. In 4,351 patients (23.0%), screening or randomization LDL-C was <70 mg/dL (median 69.4 mg/dL; interquartile range: 64.3-74.0 mg/dL); in 14,573 patients (77.0%), both determinations were ≥70 mg/dL (median 94.0 mg/dL; interquartile range: 83.2-111.0 mg/dL). RESULTS: In the lower LDL-C subgroup, MACE rates were 4.2 and 3.1 per 100 patient-years among placebo-treated patients with baseline lipoprotein(a) greater than or less than or equal to the median (13.7 mg/dL). Corresponding adjusted treatment hazard ratios were 0.68 (95% confidence interval [CI]: 0.52-0.90) and 1.11 (95% CI: 0.83-1.49), with treatment-lipoprotein(a) interaction on MACE (Pinteraction = 0.017). In the higher LDL-C subgroup, MACE rates were 4.7 and 3.8 per 100 patient-years among placebo-treated patients with lipoprotein(a) >13.7 mg/dL or ≤13.7 mg/dL; corresponding adjusted treatment hazard ratios were 0.82 (95% CI: 0.72-0.92) and 0.89 (95% CI: 0.75-1.06), with Pinteraction = 0.43. CONCLUSIONS: In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein subtilisin/kexin type 9 inhibition provides incremental clinical benefit only when lipoprotein(a) concentration is at least mildly elevated. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).
引用
- Schwartz GG, Szarek M, Bittner VA, et al. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol. 2021. PMID: 34325831. doi:10.1016/j.jacc.2021.04.102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。